Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

Schering-Plough Receives EU and US Approvals for Intravenous Formulation of Temozolomide

By Pharmaceutical Processing | March 5, 2009

Schering-PloughCorporation today announced that the European Commission and theUS FDA both approved the intravenous (IV) formulation of temozolomide as analternative to the already approved oral form of the drug. Temozolomide ismarketed as TEMODAL(R) in the EU and as TEMODAR(R) in the US. The EUCommission Decision was based on the positive opinion from the EuropeanCommittee for Medicinal Products for Human Use (CHMP) of the EuropeanMedicines Agency (EMEA) in November 2008. On January 22, 2009, the Commissionapproved a sachet packaging presentation for TEMODAL Capsules. This newpresentation provides greater patient convenience and flexibility. On February17, 2009, the Commission approved an IV formulation of TEMODAL. On February27, 2009, Schering-Plough received approval from the US FDA for the TEMODAR IVformulation. TEMODAL is a chemotherapy agent approved in the EU for treatment ofpatients with newly diagnosed glioblastoma multiforme (GBM) concomitantly withradiotherapy and subsequently as monotherapy, and for patients with malignantgliomas, such as GBM or anaplastic astrocytoma (AA), showing recurrence orprogression after standard therapy. In the US, TEMODAR is approved for thetreatment of adult patients with newly diagnosed GBM concomitantly withradiotherapy and then as maintenance treatment, as well as for refractory AA,i.e., patients who have experienced disease progression on a drug regimencontaining nitrosourea and procarbazine. “TEMODAR is a well recognized, effective treatment for patients with newlydiagnosed GBM. The newly approved IV formulation of TEMODAR provides patientswith an important alternative method of administration, and the EuropeanTEMODAL sachet presentation offers flexibility and a convenient alternativeform of packaging,” said Robert J. Spiegel, M.D., chief medical officer andsenior vice president, Schering-Plough Research Institute. “These two newoptions recognize Schering-Plough’s commitment to providing effectivetreatments in a variety of presentations for specific patient needs andpatient convenience.”

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE